Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 5/20 | 0.77 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6563388 | 0.93 | GRIA4 (0.69) | GRIA4GRIA1ALDH1A1MEN1KMT2A | |
| SCHEMBL5877603 | 0.91 | GRIA4 (0.67) | GRIA4GRIA1ALDH1A1MEN1KMT2A | |
| SCHEMBL7166935 | 0.90 | GRIA4 (0.66) | GRIA4ALDH1A1CA12CA9CA14 | |
| SCHEMBL6562905 | 0.88 | GRIA4 (0.63) | GRIA4GRIA1ALDH1A1MEN1KMT2A | |
| SCHEMBL6762111 | 0.88 | GRIA4 (0.63) | GRIA4GRIA1ALDH1A1MEN1KMT2A | |
| SCHEMBL6563315 | 0.87 | GRIA4 (0.62) | GRIA4GRIA1ALDH1A1MEN1KMT2A | |
| SCHEMBL11176545 | 0.87 | GRIA4 (0.62) | GRIA4GRIA1ALDH1A1MEN1KMT2A | |
| SCHEMBL5186022 | 0.87 | GRIA4 (0.62) | GRIA4GRIA1ALDH1A1MEN1KMT2A | |
| SCHEMBL6563303 | 0.87 | GRIA4 (0.80) | GRIA4GRIA1ALDH1A1MEN1KMT2A | |
| SCHEMBL5877567 | 0.87 | GRIA4 (0.64) | GRIA4GRIA1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213700-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CELL-SPECIFIC PHARMACOLOGY | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. | 2025-07-03 | — | — | US | claimed |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| WO-2023225369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CELL-SPECIFIC PHARMACOLOGY | DUKE UNIVERSITY (US) | 2023-11-23 | — | — | WO | claimed |
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20260071276-A1 | GPCR LATROPHILIN-3 AS BIOMARKER FOR DETECTING INCREASED RISK FOR MILD BRAIN INJURY AND METHODS OF USE THEREOF FOR DIAGNOSIS AND TREATMENT OF THE SAME | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250213700-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CELL-SPECIFIC PHARMACOLOGY | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2023225369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CELL-SPECIFIC PHARMACOLOGY | DUKE UNIVERSITY (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-115903739-A | Automated testing method, system, device and medium for distributed control system | 国核自仪系统工程有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-1296945-B1 | SULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6703425-B2 | ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2004-03-09 | — | — | US | disclosed |
| US-20030229102-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| EP-1296945-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001096289-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071276-A1 | GPCR LATROPHILIN-3 AS BIOMARKER FOR DETECTING INCREASED RISK FOR MILD BRAIN INJURY AND METHODS OF USE THEREOF FOR DIAGNOSIS AND TREATMENT OF THE SAME | GPR3, OPRL1, ADGRF1 | GRIA4 841/4885GRIA1 539/4885ALDH1A1 2893/4885 |
| US-20250213700-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CELL-SPECIFIC PHARMACOLOGY | DDT, ABCG2, CES2 | GRIA4 1860/4885GRIA1 2430/4885ALDH1A1 179/4885 |
| US-20030229102-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, SLC1A2 | GRIA4 17/4885GRIA1 9/4885ALDH1A1 270/4885 |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GRIN2A, GRIN1, GRIN3A | GRIA4 22/4885GRIA1 20/4885ALDH1A1 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.